Can-Fite BioPharma (CANF) shares jumped 43% in Wednesday trading after the company said its phase 2a study of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durable survival in a subset of heavily pretreated patients.

The open-label trial enrolled 20 patients with advanced pancreatic ductal adenocarcinoma, an aggressive form of pancreatic cancer, who had progressed after standard treatment, according to a statement.

Among eight evaluable patients treated as third-line therapy who survived at least two months after treatment initiation, median overall survival exceeded five months, with 37.5% surviving seven months or longer, according to the company.

Can-Fite said it plans to advance Namodenoson into a Phase 2b study combining it with chemotherapy.

Price: 4.24, Change: +1.27, Percent Change: +42.76